HOME >> BIOLOGY >> NEWS
The biggest isn't always best when it comes to treating cancer

Developing immunotherapeutic approaches to treat individuals with cancer is an area of intensive investigation. One such approach being developed is the generation of cancer vaccines containing peptides that mimic tumor antigens (known as mimotopes) to induce potent tumor-specific T cell responses. However, previous studies have indicated that the magnitude of a tumor antigenspecific T cell response in vitro does not always correlate with tumor regression in vivo.

Now, in a study appearing online on August 24 in advance of publication in the September print issue of the Journal of Clinical Investigation, Jill Slansky and colleagues from the University of Colorado have shown that mice vaccinated with mimotopes that induce in vitro T cell responses of intermediate magnitude are protected against tumor growth. By contrast, mimotopes that induce in vitro T cell responses of high magnitude do not protect mice from tumor growth. Both types of mimotope caused T cells to infiltrate the tumors, but only the T cells activated by mimotopes inducing in vitro T cell responses of intermediate magnitude produced the soluble factor interferon-gamma, which is important for effective tumor-specific T cell responses. This study has important implications for the further development of cancer vaccines containing mimotopes, as many current studies have used the magnitude of a tumor-specific T cell response to identify the best mimotope for the vaccine.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
24-Aug-2006


Page: 1

Related biology news :

1. What we can learn from the biggest extinction in the history of Earth
2. Leanest teens are biggest energy users and consumers
3. Polarsterns biggest fish catch in 24 years of research in Antarctic waters
4. The biggest bug in gut discomfort
5. Yale dean addresses biggest environmental threats in new book
6. Greenhouse theory smashed by biggest stone
7. The biggest family tree ever
8. New evidence indicates biggest extinction wasnt caused by asteroid or comet
9. One Wwox isnt enough (to protect against cancer)
10. In stretching, pain doesnt equal gain; but if NO isnt producing, stretching wont help
11. How sweet it isnt -- preference for alternatives to sugar based on sour, bitter tastes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The biggest isn always best when comes treating cancer

(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
(Date:5/29/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... that results of a large, European single-center experience ... hepatic metastases with the Delcath Hepatic CHEMOSAT ® ... abstract at the American Society of Clinical Oncology ...
(Date:5/29/2015)... 29, 2015  Caris Life Sciences® today announced ... which researchers utilized Caris Molecular Intelligence®, the company,s ... therapeutic targets in patients with colorectal and pancreatic ... cell death protein 1 (PD-1) and its ligand, ... the 2015 American Society of Clinical Oncology Annual ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cytogenetics ... offering. This report deals with cytogenetics ... use mainly to describe the chromosome structure and ... of molecular biology, it is also referred to ...
(Date:5/29/2015)... MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015 ... oncolytic virus talimogene laherparepvec and its ability to reduce ... the treatment have been published in the Journal of ... 436 patients with stages IIIB, IIIC and IV melanoma, ... goal of the study was to evaluate the safety ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
Cached News: